Search

Your search keyword '"Horigome, Yuichi"' showing total 15 results
Start Over Author "Horigome, Yuichi"
15 results on '"Horigome, Yuichi"'

1. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

Author

Horigome, Yuichi, Iino, Masaki, Harazaki, Yoriko, Kobayashi, Takahiro, Handa, Hiroshi, Hiramatsu, Yasushi, Kuroi, Taiga, Tanimoto, Kazuki, Matsue, Kosei, Abe, Masahiro, Ishida, Tadao, Ito, Shigeki, Iwasaki, Hiromi, Kuroda, Junya, Shibayama, Hirohiko, Sunami, Kazutaka, Takamatsu, Hiroyuki, Tamura, Hideto, Hayashi, Toshiaki, Akagi, Kiwamu, Maeda, Takahiro, Yoshida, Takahiro, Mori, Ikuo, Shinozaki, Tomohiro, and Iida, Shinsuke

Published
2024
Full Text
View/download PDF

2. ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Author

Kogure, Yasunori, Handa, Hiroshi, Ito, Yuta, Ri, Masaki, Horigome, Yuichi, Iino, Masaki, Harazaki, Yoriko, Kobayashi, Takahiro, Abe, Masahiro, Ishida, Tadao, Ito, Shigeki, Iwasaki, Hiromi, Kuroda, Junya, Shibayama, Hirohiko, Sunami, Kazutaka, Takamatsu, Hiroyuki, Tamura, Hideto, Hayashi, Toshiaki, Akagi, Kiwamu, Shinozaki, Tomohiro, Yoshida, Takahiro, Mori, Ikuo, Iida, Shinsuke, Maeda, Takahiro, and Kataoka, Keisuke

Published
2024
Full Text
View/download PDF

5. ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Author

Kogure, Yasunori, primary, Handa, Hiroshi, additional, Ito, Yuta, additional, Ri, Masaki, additional, Horigome, Yuichi, additional, Iino, Masaki, additional, Harazaki, Yoriko, additional, Kobayashi, Takahiro, additional, Abe, Masahiro, additional, Ishida, Tadao, additional, Ito, Shigeki, additional, Iwasaki, Hiromi, additional, Kuroda, Junya, additional, Shibayama, Hirohiko, additional, Sunami, Kazutaka, additional, Takamatsu, Hiroyuki, additional, Tamura, Hideto, additional, Hayashi, Toshiaki, additional, Akagi, Kiwamu, additional, Shinozaki, Tomohiro, additional, Yoshida, Takahiro, additional, Mori, Ikuo, additional, Iida, Shinsuke, additional, Maeda, Takahiro, additional, and Kataoka, Keisuke, additional

Published
2024
Full Text
View/download PDF

6. A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

Author

Horigome, Yuichi, primary, Iino, Masaki, additional, Harazaki, Yoriko, additional, Kobayashi, Takahiro, additional, Handa, Hiroshi, additional, Hiramatsu, Yasushi, additional, Kuroi, Taiga, additional, Tanimoto, Kazuki, additional, Matsue, Kosei, additional, Abe, Masahiro, additional, Ishida, Tadao, additional, Ito, Shigeki, additional, Iwasaki, Hiromi, additional, Kuroda, Junya, additional, Shibayama, Hirohiko, additional, Sunami, Kazutaka, additional, Takamatsu, Hiroyuki, additional, Tamura, Hideto, additional, Hayashi, Toshiaki, additional, Akagi, Kiwamu, additional, Maeda, Takahiro, additional, Yoshida, Takahiro, additional, Mori, Ikuo, additional, Shinozaki, Tomohiro, additional, and Iida, Shinsuke, additional

Published
2023
Full Text
View/download PDF

7. P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE

Author

Kogure, Yasunori, primary, Handa, Hiroshi, additional, Ito, Yuta, additional, Ri, Masaki, additional, Horigome, Yuichi, additional, Iino, Masaki, additional, Harazaki, Yoriko, additional, Kobayashi, Takahiro, additional, Abe, Masahiro, additional, Ishida, Tadao, additional, Ito, Shigeki, additional, Iwasaki, Hiromi, additional, Kuroda, Junya, additional, Shibayama, Hirohiko, additional, Sunami, Kazutaka, additional, Takamatsu, Hiroyuki, additional, Tamura, Hideto, additional, Hayashi, Toshiaki, additional, Akagi, Kiwamu, additional, Shinozaki, Tomohiro, additional, Yoshida, Takahiro, additional, Mori, Ikuo, additional, Iida, Shinsuke, additional, Maeda, Takahiro, additional, and Kataoka, Keisuke, additional

Published
2023
Full Text
View/download PDF

8. P-248: A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in 295 Japanese patients with relapsed/refractory multiple myeloma

Author

Iino, Masaki, primary, Horigome, Yuichi, additional, Harazaki, Yoriko, additional, Kobayashi, Takahiro, additional, Handa, Hiroshi, additional, Hiramatsu, Yasushi, additional, Kuroi, Taiga, additional, Tanimoto, Kazuki, additional, Matsue, Kosei, additional, Yoshida, Takahiro, additional, Mori, Ikuo, additional, Abe, Masahiro, additional, Akagi, Kiwamu, additional, Hayashi, Toshiaki, additional, Ishida, Tadao, additional, Ito, Shigeki, additional, Iwasaki, Hiromi, additional, Kuroda, Junya, additional, Maeda, Takahiro, additional, Shibayama, Hirohiko, additional, Sunami, Kazutaka, additional, Takamatsu, Hiroyuki, additional, Tamura, Hideto, additional, Shinozaki, Tomohiro, additional, and Iida, Shinsuke, additional

Published
2022
Full Text
View/download PDF

14. [Acute leukemia developing in the second trimester of pregnancy].

Author

Horigome Y, Tadera N, Michishita Y, Motohashi T, Ishida T, Okina S, Kamata H, Miyazaki K, and Suzuki T

Subjects
Acute Disease, Cesarean Section, Female, Humans, Pregnancy, Pregnancy Trimester, Second, Leukemia, Myeloid, Acute, Pregnancy Complications, Neoplastic
Abstract

Acute leukemia (AL) during pregnancy poses a substantial risk to both mothers and fetuses. Treatment for leukemia should be initiated promptly; however, the management of AL in pregnant women and fetuses is usually challenging, especially during the second trimester. Here, we report two cases of AL that developed during the second trimester of pregnancy. In one case, chemotherapy was initiated while continuing the pregnancy; in the second case, a cesarean section was performed prior to chemotherapy initiation. As per current medical records, both infants are thriving without any medical problems. The optimal strategy for the treatment of AL during pregnancy typically includes chemotherapy after delivery. However, if fetal development is not sufficient for ex utero survival, the only alternatives available are the initiation of treatment while continuing the pregnancy or treatment after therapeutic abortion (if it is legally allowed). According to previous studies and as per the results from our first case, the initiation of chemotherapy while sustaining the pregnancy may be an acceptable option if it is conducted with appropriate informed consent. The treatment of AL in the second trimester of pregnancy should be carefully decided, while taking into account the medical, legal, and social aspects, such as gestational weeks, maternal and fetal status, and wishes of the patients and their families.

Published
2020
Full Text
View/download PDF

15. [Coagulation disorder].

Author

Horigome Y and Higashihara M

Subjects
Anti-Inflammatory Agents, Non-Steroidal adverse effects, Blood Coagulation Disorders diagnosis, Blood Coagulation Disorders drug therapy, Blood Coagulation Factors biosynthesis, Fibrinolytic Agents adverse effects, Heparin adverse effects, Humans, Nucleotides, Cyclic metabolism, Platelet Aggregation Inhibitors adverse effects, Receptors, Drug antagonists & inhibitors, Blood Coagulation Disorders chemically induced
Published
2012

Catalog

Books, media, physical & digital resources
See catalog results